

DAFTAR PUSTAKA

1. Feghali, C. A. & Wright, T. M. Cytokines in acute and chronic inflammation. *Front. Biosci.* **2**, (1997).
2. Kemenkes RI. *Penyajian Pokok-Pokok Hasil Riset Kesehatan Dasar 2013*. (2013).
3. Audina, M. & Khaerati, K. Efektivitas Antiinflamasi Ekstrak Etanol Daun Sumambu (*Hyptis capitata* Jacq .) Pada Tikus Putih Jantan (*Rattus norvegicus* L .). *Bocelebes* **12**, 17–23 (2018).
4. Harvey, R. A. & Champe, P. . Farmakologi Ulasan Bergambar. in (eds. Ramadhani, C. et al.) (Buku Kedokteran EGC, 2013).
5. Subarnas, A. & Wagner, H. Analgesic and anti-inflammatory activity of the proanthocyanidin shelligueain A from *Polypodium feei* METT. *Phytomedicine* **7**, 401–405 (2000).
6. Hasanah, A. N., Levita, J., Natapoera, E. D. & Subarnas, A. Analyzing the interaction of shelligueain A: A bioactive compound of pakis tangkur (*Selliguea feei* or *Polypodium feei*) to cyclooxygenase enzyme by molecular docking. *Asian J. Chem.* **23**, 3093–3096 (2011).
7. Winter, W. P. De & Publishers, B. *Plant Resources of South-East Asia*. **15**, (2003).
8. Baek, N. I. *et al.* Shelligueain A, a novel highly sweet proanthocyanidin from the rhizomes of *Selliguea feei*. *J. Nat. Prod.* **56**, 1532–1538 (1993).
9. Nam-InBaek, Edward J.Kennelly, Leonardus B.S.Kardono, SoefjanTsauri, KosasihPadmawinata, D.Doel Soejarto, A. D. K. Flavonoids and a proanthocyanidin from rhizomes of *Selliguea feei*. **36**, 6–11 (1994).
10. Kristiani, R. D., Rahayu, D. & Subarnas, A. Aktivitas antihiperurisemia ekstrak etanol akar pakis tangkur (*Polypodium feei*) pada mencit jantan. *Bionatura-Jurnal Ilmu-ilmu Hayati dan Fis.* **15**, 156–159 (2013).
11. Kee, J. L. & Hayes, E. R. Farmakologi: Pendekatan Proses Keperawatan. in (ed. EGC) 802 (1996).
12. Baratawidjaja, K. G. & Rengganis, I. Imunologi Dasar. in (Fakultas Kedokteran Universitas Indonesia, 2016).
13. Huang, G., Huang, S. & Deng, J. Anti-Inflammatory Activities of Inotilone from *Phellinus linteus* through the Inhibition of MMP-9 , NF- κ B , and MAPK Activation In Vitro and In Vivo. **7**, (2012).


14. Kim, E. *et al.* BIOGF1K, a compound K-rich fraction of ginseng, plays an antiinflammatory role by targeting an activator protein-1 signaling pathway in RAW264.7 macrophage-like cells. *J. Ginseng Res.* **42**, 233–237 (2018).
15. Yang, E. J., Yim, E. Y., Song, G., Kim, G. O. & Hyun, C. G. Inhibition of nitric oxide production in lipopolysaccharide-activated RAW 264.7 macrophages by Jeju plant extracts. *Interdiscip. Toxicol.* **2**, 245–249 (2009).
16. Garcin, E. D. *et al.* Anchored plasticity opens doors for selective inhibitor design in nitric oxide synthase. *Nat. Chem. Biol.* **4**, 700–707 (2008).
17. Musfiroh, I. D. A., Muhtadi, A., Kartasasmita, R. E. & Tjahjono, D. H. In Silico Study of Asiatic Acid Interaction With Inducible Nitric Oxide Synthase (iNOS) and Cyclooxygenase-2 (COX-2). **5**, (2013).
18. Naismith, J. H. TNF α and the TNF Receptor Superfamily: Structure-Function Relationship (s). **195**, 184–195 (2000).
19. Mohning, M. P., Downey, G. P., Cosgrove, G. P. & Redente, E. F. *Mechanisms of Fibrosis. Idiopathic Pulmonary Fibrosis* (Elsevier Inc.). doi:10.1016/B978-0-323-54431-3.00003-2.
20. Aswad, M., Nursamsiar, Christine, L. & Hardianti, B. Studi Penambatan Molekul Senyawa-Senyawa Bioaktif dari Kulit Akar Murbei (*Morus sp .*). **23**, 85–100 (2019).
21. Novita, I. A. Terapi Dingin (Cold Therapy) dalam Penanganan Cedera Olahraga. *Medikora* **5**, 102–117 (2009).
22. Katzung, B. . Farmakologi Dasar dan Klinik. in (Buku Kedokteran EGC, 2002).
23. Lis, K., Kuzawińska, O. & Bałkowiec-iskra, E. Tumor necrosis factor inhibitors – state of knowledge. (2014) doi:10.5114/aoms.2014.47827.
24. Zullies, I. Farmakologi Molekuler target Aksi Obat dan Mekanisme Molekulernya. in 2–3 (Gadjah Mada University Press, 2015).
25. Sismindari, Jenie, R. I., Rumiayati & Meiyanto, E. Biokimia Farmasi. in 25–29 (Gadjah Mada University Press, 2017).
26. Siswandono. Soekardjo, B. Kimia Medisinal. in (Airlangga University Press, 2000).
27. Sarker, SD. Nahar, L. Kimia Untuk Mahasiswa Farmasi Bahan Kimia

- Organik. in 32-39p (Pustaka Pelajar, 2009).
28. Muchtaridi, Y. M. Teori dan Praktek Penambatan Molekul (Molekular Docking). in 15-16p, 37-38p (Unpad Press, 2018).
 29. Motiejunas, D. & Wade, R. C. Structural, energetic, and dynamic aspects of ligand-receptor interactions. *Compr. Med. Chem. II* **4**, 193–212 (2006).
 30. Morris, G. M. *et al.* Automated docking using a lamarckian genetic algorithm and an epirical binding free energy function. *J. Comput. Chem.* **19**, 1639–1662 (1998).
 31. Morris, G. M. *et al.* Software News and Updates AutoDock4 and AutoDockTools4 : Automated Docking with Selective Receptor Flexibility. (2009) doi:10.1002/jcc.
 32. Yanuar, A. Penambatan Molekular : Praktek dan Aplikasi Pada Virtual Screening. in 8p, 16-17p, 43p, 47-48p. (Fakultas Farmasi Universitas Indonesia, 2012).
 33. Martinelli A. Introduction To The Discovery Studio Visualizer [Internet]. http://www.adrianomartinelli.it/Fondamenti/Tutorial_0.pdf.
 34. Lipinski, C., Lombardo, F., Dominy, B. W. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development setting. *Adv. Drug Deliv. Rev.* 3–25 (1997).
 35. Nursamsiar, X., I. Surantaatmadja, S. & H. Tjahjono, D. Absorption, Distribution and Toxicity Prediction of Curculigoside A and its Derivatives. (2015) doi:10.2991/iccst-15.2015.7.
 36. Dermawan, D. *Pharmacophore Modelling and Molecular Docking Simulation Tutorial*. (2018). doi:10.13140/RG.2.2.13489.84324.
 37. Kolina, J., Sumiwi, S. A. & Levita, J. Mode Ikatan Metabolit Sekunder di Tanaman Akar Kuning (*Arcangelisia Flava* L.) dengan Nitrat Oksida Sintase. **8**, 50–58 (2018).
 38. Susanti, N. M. ., Laksmiani, N. P. L., Noviyanti, N. K. M., Arianti, K. M. & Duantara, I. K. Molecular Docking Terpinen-4-OL Sebagai Antiinflamasi Pada Aterosklerosis Secara In Silico. 221–228 (2019).
 39. Muttaqin, F. Z. *et al.* Molecular Docking and Molecular Dynamic Studies Of Stilbene Derivative Compounds As Sirtuin-3 (SIRT3) Histone Deacetylase Inhibitor On Melanoma Skin Cancer And Their Toxicities Prediction. **2**, 112–121 (2019).



40. Budiman, B. Peranan Protektif dan Non-Protektif Nitric Oxides (NOs) Pada Respon Imun. **31**, 74–82 (2008).
41. Enggardipta, R. A., Haniastuti, T. & Hanajani, J. Efek Eugenol Terhadap Jumlah Sel Inflamasi Pada Pulpa Gigi Molar Tikus Sprague. **2**, 66–73 (2016).
42. Ruswanto, Nofianti, T., Mardianingrum, R., Lestari, T. & Sepriliani, A. Desain dan Studi In Silico Senyawa Turunan Kuwanon-H sebagai Kandidat Obat Anti-HIV Design and In Silico Study of Kuwanon-H as Anti-HIV Drug Candidate. **4**, 57–66 (2018).
43. Listyani, T. A., Herowati, R. & Djalil, A. D. Analisis Docking Molekuler Senyawa Derivat Phthalimide sebagai Inhibitor Non-Nukleosida HIV-1 Reverse Transcriptase Molecular Docking Analysis of Derivate Phthalimide Compounds as Non-Nucleosida HIV-1 Reverse Transcriptase Inhibitor. **15**, 123–134 (2019).
44. Sulastri, S. *et al.* Studi In Silico Senyawa Turunan Flavonoid terhadap Enzim HMG- CoA Reduktase Study In Silico Flavonoid Derivate Compounds on The Enzyme HMG- CoA Reductase.
45. Nursamsiar, Toding, A. T. & Awaluddin, A. Studi In Silico Senyawa Turunan Analog Kalkon dan Pirimidin Sebagai Antiinflamasi: Prediksi Absorpsi, Distribusi, dan Toksisitas. **13**, 92–100 (2016).
46. Mehta, V., Chadha, R. & Dhingra, N. Pyrazolic Chalcone Derivatives Targeting Cyclin Dependant Kinase : In-Silico Molecular Docking , ADME and Druglikeness Studies. **2**, 8–15 (2018).

LAMPIRAN 1

ALUR PENELITIAN



Gambar III.1 Alur penelitian penambatan molekul

**LAMPIRAN 1
(LANJUTAN)****Gambar III.2** Analisis *lipinski's rule of five***Gambar III.3** Analisis *pre-ADME* dan toksisitas

LAMPIRAN 2
TANAMAN AKAR PAKIS TANGKUR




Gambar IV.1 Tanaman akar pakis tangkur (*Polypodium feei* METT)




LAMPIRAN 3

SITUS DAN APLIKASI



Gambar IV.2 Tampilan situs *Protein Data Bank* (PDB)



Gambar IV.3 Tampilan situs *pubchem*

LAMPIRAN 3 (LANJUTAN)

Supercomputing Facility for Bioinformatics & Computational Biology, IIT Delhi

Home | Group | Publications | Resources | Webmail | Contact Us

Lipinski Rule of Five

Lipinski rule of 5 helps in distinguishing between drug like and non drug like molecules. It predicts high probability of success or failure due to drug likeness for molecules complying with 2 or more of the following rules

- Molecular mass less than 500 Dalton
- High lipophilicity (expressed as LogP less than 5)
- Less than 5 hydrogen bond donors
- Less than 10 hydrogen bond acceptors
- Molar refractivity should be between 40-130

These filters help in early preclinical development and could help avoid costly late-stage preclinical and clinical failures .To draw a chemical structure [Click Here](#) and follow the instructions given.

Step 1: Input Drug File.

Input PDB file

Step 2 : Input pH Value

pH Value [Value ranges from 0.0 to 14.0]

Step 3: Click on 'Submit' to submit your job

Result

```

mass: 274.000000
hydrogen bond donor: 4
hydrogen bond acceptors: 5
LOGP: 1.840499
Molar Refractivity: 70.958176
  
```

Gambar IV.4 Tampilan situs *lipinski rule of five*

MDL mol and sd file | Molecular descriptors | Druglikeness | ADME Prediction | Toxicity prediction | Log In | Register

Pre-ADMET

+82 2 393 9550-1 | webmaster@bmdrc.kr

8138A, YONSEI ENGINEERING RESEARCH COMPLEX, YONSEI UNIVERSITY, SEOUL, REPUBLIC OF KOREA.

Home | About | Druglikeness | **ADME** | Toxicity | Community | Commercial


ADME

Home / ADME


Oc1ccc(O)cc1O[C@@H]2c3c(O)cc(O)cc3O[C@H]2O

Gambar IV.5 Tampilan situs *pre-ADMET*

LAMPIRAN 3 (LANJUTAN)




Gambar IV.6 Tampilan aplikasi *discovery studio visualizer*®




Gambar IV.7 Tampilan aplikasi *autodock tools*®

LAMPIRAN 3 (LANJUTAN)




Gambar IV.8 Tampilan aplikasi *chemdraw office*®




Gambar IV.9 Tampilan aplikasi *chem3D*®

LAMPIRAN 4

STRUKTUR 3D MAKROMOLEKUL




Gambar IV.10 Reseptor TNF- α dengan PDB ID 3EWJ




Gambar IV.11 Enzim iNOS dengan PDB ID 1NSI

LAMPIRAN 5
STRUKTUR 3D LIGAN ALAMI




Gambar IV.12 Ligan alami dari reseptor TNF- α




Gambar IV.13 Ligan alami dari enzim iNOS


LAMPIRAN 6
STRUKTUR 2D LIGAN UJI




Gambar IV.14 (+)-afzelechin




Gambar IV.15 3'-deoxydryopteretic acid



Gambar IV.16 Selliguelain A




Gambar IV.17 Selliguelain B




Gambar IV.18

Kaempferol-3-O- β -D-glukopyranoside-7-O- α -L-rhamnopyranoside


**LAMPIRAN 6
(LANJUTAN)**



Gambar V.19 (+)-afzelechin-O- β -4'-D-glukopyranoside




Gambar V.20 Geranin A



Gambar IV.21


2-((2R,3R)-3,5,7-trihydroxy-2-(4-hydroxyphenyl)-8-((6R,10R,15R)-1,3,9,11,15-pentahydroxy-6,12-bis(4-hydroxyphenyl)-11,12,13,14-tetrahydro-10H-6,14-methanobenzo[d]naphtho[1,2-g][1,3]dioxocin-10-yl) chroman-4-yl)acetic acid

**LAMPIRAN 6
(LANJUTAN)**




Gambar IV.22

(4S,8S,15R)-4-(benzylthio)-2,8-bis(4-hydroxyphenyl)-3,4-dihydro-2H,14H-8,14-methanobenzo[7,8][1,3]dioxocino[4,5-H]chromene-3,5,11,13,15-pentaol



Gambar IV.23


Undecaacetate of epiafzelechin-(4 β →8,2 β →O→7)-epiafzelechin-(4 β →8)-3'-deoxydryopterac acid methyl ester




Gambar IV.24 Undecetylepiafzelechin-(4 β →8,2 β →O→7)-epiafzelechin-(4 β →8)-afzelechin

LAMPIRAN 7

VALIDASI METODE




Gambar V.1 Hasil visualisasi tumpang tindih ligan alami dari enzim iNOS hasil kristalografi sinar-X (biru) dengan ligan hasil *redocking* (hijau)




Gambar V.2 Hasil visualisasi interaksi ligan alami dengan enzim iNOS

LAMPIRAN 7 (LANJUTAN)



Gambar V.3 Hasil visualisasi tumpang tindih ligan alami dari reseptor TNF- α hasil kristalografi sinar-X (biru) dengan ligan hasil *redocking* (hijau)



Gambar V.4 Hasil visualisasi interaksi ligan alami dengan reseptor TNF- α

**LAMPIRAN 7
(LANJUTAN)****Tabel V.1**
Grid Box, RMSD, dan Nilai Energi Bebas Ligan Alami

Kode Reseptor	Grid Box	RMSD (Å)	Energi Bebas Ligan Alami
1NSI	X : 9.756 Y : 64.46 Z : 15.994	1,817	-7,03
3EWJ	X : 48.607 Y : 30.91 Z : 43.381	0,681	-13,66

LAMPIRAN 8

HASIL PENAMBATAN MOLEKUL

Tabel V.2

Hasil Penambatan Molekul Ligan Alami dan Senyawa Uji pada Reseptor TNF- α

Ligan/Senyawa	Energi Bebas (ΔG) kkal/mol	KI (μM)	Jumlah Ikatan Hidrogen	Residu Asam Amino
Ligan Alami				
(1S,3R,6S)-4-oxo-6-{4-[(2-phenylquinolin-4-yl)methoxy]phenyl}-5-azaspiro[2.4]heptane-1-carboxylic acid	-13,66	$9,76 \times 10^{-5}$	3	HIS B:415 LEU B:348 GLY B:349
Ligan Uji				
Geranin A	-8,65	0,453	2	TYR B:433 GLU B:406
Selligueain B	+80,64	-	5	GLY B:346 GLY B:349 GLU B:406 GLU B:398 ASN B:447
3'-deoxydryopteris acid	-8,02	1,32	6	PRO B:437 VAL B:434 VAL B: 440 TYR B:436 ILE B:438 GLU B:398
(4S,8S,15R)-4-(benzylthio)-2,8-bis(4-hydroxyphenyl)-3,4-dihydro-2H,14H-8,14-methanobenzo[7,8][1,3]dioxocino[4,5-h]chromene-3,5,11,13,15-pentaol	-5,40	110,78	2	GLY B:349 PRO B:437

**LAMPIRAN 8
(LANJUTAN)**

**Tabel V.2
Lanjutan**

Ligan/Senyawa	Energi Bebas (ΔG) kkal/mol	KI (μM)	Jumlah Ikatan Hidrogen	Residu Asam Amino
Undecaacetyl epiafzelechin-(4 β -8,2 β -0-7)-epiafzelechin-(4 β -8)-afzelechin	+598,81	-	1	THR B:347
Kaempferol-3-O- β -D-glucopyranoside-7-O- α -L-rhamnopyranoside	-10,83	0,011	7	ASN B:447 ILE B:438 TYR B:436 HIS B:405 GLU B:406 GLY B:349 THR B:347
(+)-afzelechin-O- β -4'-D-glucopyranoside	-10,38	0,025	5	VAL B:440 VAL B:434 PRO B:437 LEU B:348 GLY B:349
2-((2R,3R)-3,5,7-trihydroxy-2-(4-hydroxyphenyl)-8-(((6R,10R,15R)-1,3,9,11,15-pentahydroxy-6,12-bis(4-hydroxyphenyl)-11,12,13,14-tetrahydro-10H-6,14-methanobenzo[d]naphtho[1,2-g][1,3]dioxocin-10-yl)chroman-4-yl)acetic acid	+52,34	-	7	GLY B:346 GLY B:349 GLU B:398 GLU B:406 PRO B:437 ASN B:447 VAL B:440

**LAMPIRAN 8
(LANJUTAN)**

**Tabel V.2
Lanjutan**

Ligan/Senyawa	Energi Bebas (ΔG) kkal/mol	KI (μM)	Jumlah Ikatan Hidrogen	Residu Asam Amino
Undeca acetate of epiafzelechin-(4 β →8, 2 β →O→7)-epiafzelechin-(4 β →8)-3'-deoxydryopteris acid methyl ester	+751,31	-	-	-
Selligueain A	+120,29	-	7	ASN B:447 ALA B:351 GLU B:406 GLY B:346 GLY B:349 PRO B:437 LEU B:401
(+)-afzelechin	-7,59	2,71	2	ILE B:438 PRO B:437

**LAMPIRAN 8
(LANJUTAN)**

Tabel V.3
Hasil Penambatan Molekul Ligan Alami dan Senyawa Uji pada Enzim iNOS

Ligan/Senyawa	Energi Bebas (ΔG) kcal/mol	KI (μM)	Jumlah Ikatan Hidrogen	Residu Asam Amino
Ligan Alami				
Arginine	-7,03	7,02	5	PRO A:350 ASP A: 382 ARG A:266 GLN A:263 GLU A:377
Ligan Uji				
Geranin A	-7,79	1,95	2	ASP A:382 ARG A:199
Selligecain B	-2,38	17980	9	ILE A:201 PRO A:350 ARG A:381 ARG A:388 TYR A:373 TYR A:347 ASP A:382 TRP A:346 GLN A:263
3'-deoxydryopteric acid	-7,40	3,77	4	TRP A:372 PRO A:350 PHE A:369 ARG A:199
(4S,8S,15R)-4-(benzylthio)-2,8-bis(4-hydroxyphenyl)-3,4-dihydro-2H,14H-8,14-methanobenzo[7,8][1,3]dioxocino[4,5-h]chromene-3,5,11,13,15-pentaol	-6,59	14,80	2	ALA A:262 MET A:434

**LAMPIRAN 8
(LANJUTAN)**

**Tabel V.3
Lanjutan**

Ligan/Senyawa	Energi Bebas (ΔG) kcal/mol	KI (μM)	Jumlah Ikatan Hidrogen	Residu Asam Amino
Undecaacetyl epiafzelechin-(4 β -8,2 β -0-7)-epiafzelechin-(4 β -8)-afzelechin	+569,52	-	4	MET A:374 TYR A:267 CYS A:200 ARG A:199
Kaempferol-3-O- β -D-glucopyranoside-7-O- α -L-rhamnopyranoside	-6,75	11,34	5	TRP A:372 CYS A:200 MET A:355 GLU A:377 GLY A:202
(+)-afzelechin-O-β-4'-D-glucopyranoside	-9,20	0,179	9	GLU A:377 ARG A:199 ILE A:201 TRP A:372 TYR A:373 TYR A:347 GLN A:263 ARG A:388 ASP A:382
2-((2R,3R)-3,5,7-trihydroxy-2-(4-hydroxyphenyl)-8-((6R,10R,15R)-1,3,9,11,15-pentahydroxy-6,12-bis(4-hydroxyphenyl)-11,12,13,14-tetrahydro-10H-6,14-methanobenzo[d]naphtho[1,2-g][1,3]dioxocin-10-yl)chroman-4-yl)acetic acid	-0,25	656120	7	PRO A:350 ILE A:201 TYR A:347 TYR A:373 ASP A:382 ARG A:388 GLN A:263

**LAMPIRAN 8
(LANJUTAN)**

**Tabel V.3
Lanjutan**

Ligan/Senyawa	Energi Bebas (ΔG) kcal/mol	KI (μM)	Jumlah Ikatan Hidrogen	Residu Asam Amino
Undeca acetate of epiafzelechin-(4 β →8, 2 β →O→7)-epiafzelechin-(4 β →8)-3'-deoxydryopteris acid methyl ester	+255,66	-	3	ASN A:283 ARG A:388 CYS A:200
Selligueain A	+11,47	-	5	MET A:434 PRO A:350 ALA A:262 ARG A:388 GLU A:377
(+)-afzelechin	-7,28	4,62	4	ARG A:199 TRP A:372 PRO A:350 PHE A:369

LAMPIRAN 9

HASIL PENGUJIAN *LIPINSKI'S RULE OF FIVE*

Tabel V.4

Prediksi *Drug Likeness* Senyawa Akar Pakis Tangkur (*Polypodium feei* METT)
Berdasarkan Aturan *Lipinski's Rule of Five*

Senyawa Uji	Donor Ikatan Hidrogen	Akseptor Ikatan Hidrogen	Bobot Molekul	Log P	Memenuhi Syarat/ Tidak
(+)-afzelechin	4	5	274	1,84	Memenuhi
Geranin A	7	10	544	3,38	Tidak memenuhi
Kaempferol-3-O- β -D-glucopyranoside-7-O- α -L-rhamnopyranoside	9	14	592	-1,48	Tidak memenuhi
3'-deoxydryopteris acid	5	7	332	1,86	Memenuhi
(4S,8S,15R)-4-(benzylthio)-2,8-bis(4-hydroxyphenyl)-3,4-dihydro-2H,14H-8,14-methanobenzo[7,8][1,3]dioxocino[4,5-H]chromene-3,5,11,13,15-pentaol	7	10	652	5,67	Tidak memenuhi
Selligueain A	11	15	816	3,98	Tidak memenuhi
Selligueain B	11	16	886	5,44	Tidak memenuhi
Undecaacetyl epiafzelechin-(4 β -8,2 β -0-7)-epiafzelechin-(4 β -8)-afzelechin	0	25	1276	8,80	Tidak memenuhi

**LAMPIRAN 9
(LANJUTAN)**

**Tabel V.4
Lanjutan**

Senyawa Uji	Donor Ikatan Hidrogen	Akseptor Ikatan Hidrogen	Bobot Molekul	Log P	Memenuhi Syarat/ Tidak
(+)-afzelechin-O- β -4'-D-glucopyranoside	7	10	436	-0,69	Tidak memenuhi
2-((2R,3R)-3,5,7-trihydroxy -2-(4-hydroxyphenyl)-8-((6R,10R,15R)-1,3,9,11,15-pentahydroxy-6,12-bis(4-hydroxyphenyl)-11,12,13,14-tetrahydro-10H-6,14-methanobenzo[d]naphtho[1,2-g][1,3]dioxocin-10-yl)chroman-4-yl)acetic acid	12	16	872	5,35	Tidak memenuhi
Undeca acetate of epiafzelechin-(4 β →8, 2 β →O→7)-epiafzelechin-(4 β →8)-3'-deoxydryopteris acid methyl ester	0	27	1348	8,91	Tidak memenuhi

Donor ikatan hidrogen : Tidak lebih dari 5

Akseptor ikatan hidrogen : Tidak lebih dari 10

Bobot molekul : Tidak lebih dari 500 g/mol

Log P : Tidak lebih dari 5

LAMPIRAN 10

HASIL PENGUJIAN *Pre-ADME*

Tabel V.5

Hasil Prediksi Profil Absorpsi dan Distribusi Senyawa Akar Pakis Tangkur
(*Polypodium feei* METT)

No	Senyawa/Ligan	Absorpsi		Distribusi
		Caco-2 cell (nm sec-1)	HIA (%)	Protein Plasma Binding (%)
1	Geranin A	11,80 ^b	73,11 ^a	100,0 ^a
2	Selligueain B	16,81 ^b	48,56 ^b	100,0 ^a
3	3'-deoxydryopteris acid	13,87 ^b	69,23 ^b	87,44 ^b
4	(4S,8S,15R)-4-(benzylthio)-2,8-bis(4-hydroxyphenyl)-3,4-dihydro-2H,14H-8,14-methanobenzo[7,8][1,3]dioxocino[4,5-H]chromene-3,5,11,13,15-pentaol	17,64 ^b	86,09 ^a	100,0 ^a
5	Undecaacetyl epiafzelechin-(4 β -8,2 β -0-7)-epiafzelechin-(4 β -8)-afzelechin	21,02 ^b	98,04 ^a	100,0 ^a
6	Kaempferol-3-O- β -D-glucopyranoside-7-O- α -L-rhamnopyranoside	6,99 ^b	5,43 ^c	40,36 ^b
7	(+)-afzelechin-O-β-4'-D-glucopyranoside	2,40 ^c	31,42 ^b	65,20 ^b
8	Undeca acetate of epiafzelechin-(4 β \rightarrow 8, 2 β \rightarrow O \rightarrow 7)-epiafzelechin-(4 β \rightarrow 8)-3'-deoxydryopteris acid methyl ester	21,00 ^b	98,13 ^a	100,0 ^a
9	Selligueain A	15,40 ^b	54,23 ^b	100,0 ^a

LAMPIRAN 10
(LANJUTAN)

Tabel V.5
Lanjutan

No	Senyawa/Ligan	Absorpsi		Distribusi
		Caco-2 cell (nm sec-1)	HIA (%)	Protein Plasma Binding (%)
10	(+)-afzelechin	1,29 ^c	80,41 ^a	100,0 ^a
11	2-((2R,3R)-3,5,7-trihydroxy -2-(4-hydroxyphenyl)-8-((6R,10R,15R)-1,3,9,11,15-pentahydroxy-6,12-bis(4-hydroxyphenyl)-11,12,13,14-tetrahydro-10H-6,14-methanobenzo[d] naphtho[1,2-g][1,3]dioxocin-10-yl)chroman-4-yl)acetic acid	16,73 ^b	38,26 ^b	100,0 ^a

Keterangan: HIA (*Human Intestinal Absorpsi*) = (a) 70-100% *well absorbed*
 (b) 20-70 *moderately absorbed*
 (c) 0-20% *poorly absorbed*

In Vitro CaCo-2 cell permeability = (a) > 70 *higher permeability*
 (b) 4-70 *medium permeability*
 (c) < 4 *low permeability*

Plasma Protein Binding = (a) > 90% *strongly bound*
 (b) < 90% *weakly bound*

LAMPIRAN 11
HASIL PENGUJIAN TOKSISITAS

Tabel V.6

Hasil Prediksi Toksisitas Senyawa Akar Pakis Tangkur (*Polypodium feei* METT)

No	Senyawa/Ligan	Mutagenik	Karsinogenik
		Mutagen / Non Mutagen	(-) / (+)
1	Geranin A	Non-Mutagen	Negatif
2	Selligueain B	Non-Mutagen	Negatif
3	3'-deoxydryopteris acid	Mutagen	Negatif
4	(4S,8S,15R)-4-(benzylthio)-2,8-bis(4-hydroxyphenyl)-3,4-dihydro-2H,14H-8,14-methanobenzo[7,8][1,3]dioxocino[4,5-h]chromene-3,5,11,13,15-pentaol	Non-Mutagen	Negatif
5	Undecaacetyl epiafzelechin-(4 β -8,2 β -0-7)-epiafzelechin-(4 β -8)-afzelechin	Mutagen	Positif
6	Kaempferol-3-O- β -D-glucopyranoside-7-O- α -L-rhamnopyranoside	Non-Mutagen	Negatif
7	(+)-afzelechin-O-β-4'-D-glucopyranoside	Mutagen	Negatif
8	Undeca acetate of epiafzelechin-(4 β \rightarrow 8, 2 β \rightarrow O \rightarrow 7)-epiafzelechin-(4 β \rightarrow 8)-3'-deoxydryopteris acid methyl ester	Mutagen	Positif
9	Selligueain A	Non-Mutagen	Negatif
10	(+)-afzelechin	Mutagen	Negatif

**LAMPIRAN 11
(LANJUTAN)**

**Tabel V.6
Lanjutan**

No	Senyawa/Ligan	Mutagenik	Karsinogenik
		Mutagen / Non Mutagen	(-) / (+)
11	2-((2R,3R)-3,5,7-trihydroxy-2-(4-hydroxyphenyl)-8-((6R,10R,15R)-1,3,9,11,15-pentahydroxy-6,12-bis(4-hydroxyphenyl)-11,12,13,14-tetrahydro-10H-6,14-methanobenzo[d] naphtho[1,2-g][1,3]dioxocin-10-yl)chroman-4-yl)acetic acid	Non-Mutagen	Negatif